Article
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.
Cancer immunology, immunotherapy : CII - 1 Jun 2023
Fang Bangwei, Wei Yu, Zeng Hao, Li Yonghong, Chen Shouzhen, Zhang Tingwei, Pan Jian, Wang Beihe, Wu Junlong, Jin Shengming, Gan Hualei, Hu Mengna, Zhang Ding, Ye Dingwei, Zhu Yao
Abstract excerpt
Prostate cancer (PCa) patients with mismatch repair (MMR) genes mutations are potentially responsive to immune checkpoint blockade (ICB). However, aberrations in MMR genes were rare in PCa and there is evidence that MMR genes mutations are highly ethnic specific. Thus, the prevalence and clinical characteristics of this subgroup in Chinese PCa patients are largely unknown. Furthermore, why some of these patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.